The goal of the present work was to characterize a
hydrogel material for localized spinal cord delivery. To address
spinal cord injuries, an
injectable in situ gelling system was tested utilizing a simple, effective, and rapid cross-linking method via Michael addition. Thiolated
chitosan material and
maleimide-terminated
polyethylene glycol material were mixed to form a
hydrogel and evaluated in vitro and in vivo. Three distinct thiolated
chitosan precursors were made by varying reaction conditions; a modification of
chitosan with Traut's
reagent (2-iminothiolane) displayed the most attractive
hydrogel properties once mixed with
polyethylene glycol. The final
hydrogel chosen for animal testing had a swelling ratio (Q) of 57.5 ± 3.4 and elastic modulus of 378 ± 72 Pa. After confirming low cellular toxicity in vitro, the
hydrogel was injected into the spinal cord of rats for 1 and 2 weeks to assess host reaction. The rats displayed no overt functional deficits due to injection following initial surgical recovery and throughout the 2-week period after for both the saline-injected
sham group and
hydrogel-injected group. The saline and
hydrogel-injected animals both showed a similar response from ED1+ microglia and GFAP overexpression. No significant differences were found between saline-injected and
hydrogel-injected groups for any of the measures studied, but there was a trend toward decreased affected area size from 1 to 2 weeks in both groups. Access to the central nervous system is limited by the blood-brain barrier for noninvasive
therapies; further development of the current system for localized
drug or cellular delivery has the potential to shape treatments of
spinal cord injury.